孕妇血清学标志物预测胎盘缺血性疾病的研究进展
摘要
<正>妊娠期持续的胎盘缺血性综合征,又称胎盘缺血性疾病,包括子痫前期、胎儿生长受限(FGR)/小于胎龄儿(SGA)及胎盘早剥等,是导致早产的主要因素[1]。子宫螺旋动脉重塑受阻、滋养细胞侵袭不足、胎盘着床过浅、胎盘血流灌注不足及循环障碍,母体与胎儿间物质转运障碍,影响胎儿宫内生长发育导致FGR/SGA的发生;胎盘持续缺氧、细胞凋亡,
引文
[1]Friedman AM,Cleary KL.Prediction and prevention of is chemic placental disease[J].Semin Perinatol,2014,38:177-182.
[2]杨鸿.孕中期血清β-人绒毛膜促性腺激素水平与不良妊娠结局的关系[J].检验医学与临床,2010,7(17):1846-1847.
[3]丰友吉,沈铿.妇产科学[J].第2版,北京:人民卫生出版社,2011:92.
[4]于彩霞,王会芳,胡哲英.探讨血清雌三醇和人胎盘催乳素水平与高危妊娠的关系[J].解放军医学院学报,2014,35(2):150-152.
[5]Tongprasert F,Srisupundit K,Luewan S,et al.Second trimester maternal serum markers and a predictive model for predicting fetal hemoglobin Bart's disease[J].Matern Fetal Neonatal Med,2013,26(2):146-149.
[6]Chen CP,Su YN,Lin SP,et al.Prenatal diagnosis and molecular cytogenetic characterization of a denovo interstitial duplication of 11q(11q22.3-q23.3)associated with abnormal maternal serum biochemistry[J].Taiwan J Obstet Gynecol,2013,52(1):120-124.
[7]Pherson E,Thomas GD,Manlick C,et al.Extreme values of maternal serum analysis in second trimester screening:looking beyond trisomy and NTD's[J].J Genet Counsel,2011,20(11):396-399.
[8]Spencer K,Khalil A,et al.First trimester maternal serum alpha-fetoprotein is not raised in pregnancies with open spina bifida[J].Prenatal Diagnosis,2014,34(2):168-171.
[9]Kim D,Steve T,Lesley M,et al.Maternal serum placental growth factor andα-fetoprotein testing in first trimester screening or Down syndrome[J].Prenatal Diagnosis,2013,33(5):457-461.
[10]Garcia-Cavazos R,Colin-Valenzuela A,Espinoy Sosa S.Alphafetoprotein as early predictor of adverse perinatal outcome[J].Ginecol Obster Mex,2010,78:268-274.
[11]Ay E,Kavak ZN,Elter K,et al.Screening for pre-eclampsia by using maternal serum inhibin A,activin A,human chorionic gonadotropin,unconjugated estriol,and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy[J].Aust N Z J Obstet Gynaecol,2005,45(4):283-288.
[12]Spencer K,Cowans NJ,Nicolaides KH.Low levels of maternal serum PAPP-A in the first trimester and the risk of preeclampsia[J].Prenat Diagn,2008,28(1):7-10.
[13]Gizurarson S,Huppertz B,Osol G,et al.Effects of placental protein 13 on the cardiovascular system in gravid and non-gravid rodents[J].Fetal Diagn Ther,2013,33(4):257-264.
[14]Meiri H,Osol G,Cetin I,et al,Personalized therapy against preeclampsia by replenishing placental protein 13(PP13)targeted to patients with impaired PP13 molecule or function[J].Comput Struct Biotechnol J,2017,15:433-446.
[15]Lehnen H,Mosblech N,Reineke T,et al.Prenatal clinical assessment of sF lt-1(soluble fms-like Tyrosine kinase-1)/PIGF(placental growth factor)ratio as a diagnostic tool for preeclampsia,pregnancy-induced hypertension,and proteinuria[J].Geburtshilfe Frauenheilkd,2013,73(5):444-445.
[16]Shokry M,Bedaiwy MA,Fathalla MM,et al.Maternal serum placental growth factor and soluble fms-like tyrosine kinase1 as early predictors of preeclampsia[J].Acta Obstet Gynecol Scand,2010,89(1):143-146.
[17]Rohra DK,Zeb A,Qureishi RN,et al.Prediction of preeclampsia during early pregnancy in primiparas with soluble fms-like tyrosine kinase-1 and placental growth factor[J].Natl Med J India,2012,25(2):68-73.
[18]Mijal RS,Holzman CB,Rana S,et al.Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery[J].J Matern Fetal Neonatal Med,2012,25(7):1135-1141.
[19]Powers RW,Jeyabalan A,Clifton RG,et al.Soluble fme-Liketyrosine kinase 1(sF lt-1),endoglin and placental growth factor(PIGF)in preeclampsia among high risk pregnancies[J].PLoSOne,2010,5(10):e13263.
[20]Husse S,Gottschlich A,Schrey S,et al.Predictive value of the sF ltl/PLGF ratio for the diagnosis of preeclampsia in high risk patients[J].Z Geburtshilfe Neonatol,2014,218(1):34-41.
[21]Hu XY,Bian XM,Jiang YL,et al.Relationship of adverse pregnancy outcomes and a high risk serum screen for Down syndrome in the second trimester[J].Zhonghua Fu Chan Ke Za Zhi,2012,47(6):427-430.
[22]Baer RJ,Currier RJ,Norton ME,et al.Obstetric,perinatal,and fetal outcomes in pregnancies with false-positive integrated screening results[J].Obstet Gynecol,2014,123(3):603-609.
[23]Yazdani S,Rouholahnejad R,Asnafi N,et al.Correlation of pregnancy outcome with quadruple screening test at second trimester[J].Med J Islam Repub Iran,2015,29:281.
[24]Haddow JE,McC lain MR,Lambert-Messerlian G,et al.Variability in thyroid stimulating hormone suppression by human chronic gonadotropin during early pregnancy[J].J Clin Endocinol Metab,2008,93(9):3341-3347.
[25]O’Gorman N,Wright D,Poon LC,et al.Accuracy of competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks'gestation[J].Ultrasound Obstet Gynecol,2016,48(1):72-79.
[26]Giguère Y,Charland M,Bujold E,et al.Combining biochemical and ultrasonographic markers in predicting preeclampsia:a systematic review[J].Ann Biol Clin(Paris),2011,69(3):257-271.
[27]Medrano-Uribe FA,Enríquez-Pérez MM,Reyes-Mu1oz E,et al.Prevalence of uterine anatomical anomalies in Mexican women with recurrent pregnancy loss[J].Gac Med Mex,2016,152(2):163-166.
[28]Akolekar R,Syngelaki A,Poon L,et al.Competing risk model in early screening for preeclampsia by biophysical and biochemical markers[J].Fetal Diagn Ther,2013,33(1):8-15.
[29]Savasan ZA,Goncalves LF,Bahado-Singh RO.Second and third trimester biochemical and ultrasound markers predictive of ischemic p1acental disease[J].Semin Perinatol,2014,38(3):167-176.
[2]杨鸿.孕中期血清β-人绒毛膜促性腺激素水平与不良妊娠结局的关系[J].检验医学与临床,2010,7(17):1846-1847.
[3]丰友吉,沈铿.妇产科学[J].第2版,北京:人民卫生出版社,2011:92.
[4]于彩霞,王会芳,胡哲英.探讨血清雌三醇和人胎盘催乳素水平与高危妊娠的关系[J].解放军医学院学报,2014,35(2):150-152.
[5]Tongprasert F,Srisupundit K,Luewan S,et al.Second trimester maternal serum markers and a predictive model for predicting fetal hemoglobin Bart's disease[J].Matern Fetal Neonatal Med,2013,26(2):146-149.
[6]Chen CP,Su YN,Lin SP,et al.Prenatal diagnosis and molecular cytogenetic characterization of a denovo interstitial duplication of 11q(11q22.3-q23.3)associated with abnormal maternal serum biochemistry[J].Taiwan J Obstet Gynecol,2013,52(1):120-124.
[7]Pherson E,Thomas GD,Manlick C,et al.Extreme values of maternal serum analysis in second trimester screening:looking beyond trisomy and NTD's[J].J Genet Counsel,2011,20(11):396-399.
[8]Spencer K,Khalil A,et al.First trimester maternal serum alpha-fetoprotein is not raised in pregnancies with open spina bifida[J].Prenatal Diagnosis,2014,34(2):168-171.
[9]Kim D,Steve T,Lesley M,et al.Maternal serum placental growth factor andα-fetoprotein testing in first trimester screening or Down syndrome[J].Prenatal Diagnosis,2013,33(5):457-461.
[10]Garcia-Cavazos R,Colin-Valenzuela A,Espinoy Sosa S.Alphafetoprotein as early predictor of adverse perinatal outcome[J].Ginecol Obster Mex,2010,78:268-274.
[11]Ay E,Kavak ZN,Elter K,et al.Screening for pre-eclampsia by using maternal serum inhibin A,activin A,human chorionic gonadotropin,unconjugated estriol,and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy[J].Aust N Z J Obstet Gynaecol,2005,45(4):283-288.
[12]Spencer K,Cowans NJ,Nicolaides KH.Low levels of maternal serum PAPP-A in the first trimester and the risk of preeclampsia[J].Prenat Diagn,2008,28(1):7-10.
[13]Gizurarson S,Huppertz B,Osol G,et al.Effects of placental protein 13 on the cardiovascular system in gravid and non-gravid rodents[J].Fetal Diagn Ther,2013,33(4):257-264.
[14]Meiri H,Osol G,Cetin I,et al,Personalized therapy against preeclampsia by replenishing placental protein 13(PP13)targeted to patients with impaired PP13 molecule or function[J].Comput Struct Biotechnol J,2017,15:433-446.
[15]Lehnen H,Mosblech N,Reineke T,et al.Prenatal clinical assessment of sF lt-1(soluble fms-like Tyrosine kinase-1)/PIGF(placental growth factor)ratio as a diagnostic tool for preeclampsia,pregnancy-induced hypertension,and proteinuria[J].Geburtshilfe Frauenheilkd,2013,73(5):444-445.
[16]Shokry M,Bedaiwy MA,Fathalla MM,et al.Maternal serum placental growth factor and soluble fms-like tyrosine kinase1 as early predictors of preeclampsia[J].Acta Obstet Gynecol Scand,2010,89(1):143-146.
[17]Rohra DK,Zeb A,Qureishi RN,et al.Prediction of preeclampsia during early pregnancy in primiparas with soluble fms-like tyrosine kinase-1 and placental growth factor[J].Natl Med J India,2012,25(2):68-73.
[18]Mijal RS,Holzman CB,Rana S,et al.Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery[J].J Matern Fetal Neonatal Med,2012,25(7):1135-1141.
[19]Powers RW,Jeyabalan A,Clifton RG,et al.Soluble fme-Liketyrosine kinase 1(sF lt-1),endoglin and placental growth factor(PIGF)in preeclampsia among high risk pregnancies[J].PLoSOne,2010,5(10):e13263.
[20]Husse S,Gottschlich A,Schrey S,et al.Predictive value of the sF ltl/PLGF ratio for the diagnosis of preeclampsia in high risk patients[J].Z Geburtshilfe Neonatol,2014,218(1):34-41.
[21]Hu XY,Bian XM,Jiang YL,et al.Relationship of adverse pregnancy outcomes and a high risk serum screen for Down syndrome in the second trimester[J].Zhonghua Fu Chan Ke Za Zhi,2012,47(6):427-430.
[22]Baer RJ,Currier RJ,Norton ME,et al.Obstetric,perinatal,and fetal outcomes in pregnancies with false-positive integrated screening results[J].Obstet Gynecol,2014,123(3):603-609.
[23]Yazdani S,Rouholahnejad R,Asnafi N,et al.Correlation of pregnancy outcome with quadruple screening test at second trimester[J].Med J Islam Repub Iran,2015,29:281.
[24]Haddow JE,McC lain MR,Lambert-Messerlian G,et al.Variability in thyroid stimulating hormone suppression by human chronic gonadotropin during early pregnancy[J].J Clin Endocinol Metab,2008,93(9):3341-3347.
[25]O’Gorman N,Wright D,Poon LC,et al.Accuracy of competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks'gestation[J].Ultrasound Obstet Gynecol,2016,48(1):72-79.
[26]Giguère Y,Charland M,Bujold E,et al.Combining biochemical and ultrasonographic markers in predicting preeclampsia:a systematic review[J].Ann Biol Clin(Paris),2011,69(3):257-271.
[27]Medrano-Uribe FA,Enríquez-Pérez MM,Reyes-Mu1oz E,et al.Prevalence of uterine anatomical anomalies in Mexican women with recurrent pregnancy loss[J].Gac Med Mex,2016,152(2):163-166.
[28]Akolekar R,Syngelaki A,Poon L,et al.Competing risk model in early screening for preeclampsia by biophysical and biochemical markers[J].Fetal Diagn Ther,2013,33(1):8-15.
[29]Savasan ZA,Goncalves LF,Bahado-Singh RO.Second and third trimester biochemical and ultrasound markers predictive of ischemic p1acental disease[J].Semin Perinatol,2014,38(3):167-176.